race-flame-resize-638x300

THE LUNG CANCER IMMUNOTHERAPY RACE HEATS UP!

IMMUNOTHERAPY AS AN ONCOLOGY TREATMENT PARADIGM REALLY CAME OF AGE IN 2014, WITH THE FIRST FDA APPROVALS OF ANTI-PD-1/PD-L1 THERAPIES IN ADVANCED MELANOMA. DEVELOPMENTS IN THE FIELD LOOK LIKE THEY ARE NOT SLOWING DOWN IN 2015, WITH THE RACE ON FOR APPROVAL IN THE MUCH LARGER LUNG CANCER PATIENT POPULATION. Targeting cancer by taking advantage… Read more »

high-jump-resize-638x300

FDA DRUG APPROVALS REACH NEW HEIGHTS

THE US FDA APPROVED 41 NOVEL NEW MEDICINES IN 2014, THE HIGHEST NUMBER OF APPROVALS FOR 18 YEARS. THE LIST COVERED A WIDE VARIETY OF DISEASE INDICATIONS AND INCLUDED BOTH INTERESTING ANTICANCER AND ANTIDIABETIC AGENTS, AND NOTABLY 15 ORPHAN DRUGS. WE REVIEW THE BIG HITTERS THAT MADE THE LIST, AND WHY SOME PRICEY AGENTS ARE… Read more »

darwin3-638x300

CANCER EVOLUTION: NATURALLY SELECTING DRUG RESISTANCE?

DARWIN’S THEORY OF NATURAL SELECTION WAS PUBLISHED IN 1859, EXPLAINING HOW NATURE SELECTS CERTAIN ADVANTAGEOUS PHYSICAL ATTRIBUTES (OR PHENOTYPES) TO PASS ON TO THEIR OFFSPRING, SO THAT THEY CAN BETTER SURVIVE IN THEIR ENVIRONMENT. NOW OVER 150 YEARS LATER, THE THEORY IS BECOMING A TALKING POINT IN ONCOLOGY, WITH NATURAL SELECTION WITHIN TUMORS HELPING TO… Read more »

Grading-resize-638x300

NIVOLUMAB AND CARFILZOMIB GET TOP MARKS AT ASH 2014

CROWN BIOSCIENCE ENJOYED AN INTERESTING CONFERENCE AT THE 56TH ASH ANNUAL MEETING IN SAN FRANCISCO LAST WEEK. AS WELL AS CATCHING UP WITH RESEARCHERS AND CLINICIANS TO DISCUSS OUR NEW MODELS AND DATA, WE ALSO REVIEWED THE REST OF THE CONFERENCE TO BRING YOU THE HOT HEMATOLOGY TOPICS OF THE MEETING. TOP STORIES INCLUDED THE… Read more »